Can-Fite BioPharma Ltd. (CANF) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 26, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CANF SEC filings page.
Can-Fite BioPharma Ltd. (CANF) reported $405K in revenue for fiscal year 2025, down 39.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing is the dominant business mechanic supporting a development-stage company whose operating receipts remain very small.
Cash conversion is not the main issue: in FY2025, operating activities used$8.9M while free cash flow used essentially the same amount, because capital expenditures were only$2K . The closer agreement between accounting loss and cash usage indicates that reported losses are translating into cash needs rather than being driven mainly by non-cash charges.
Development-stage economics remain pronounced: FY2025 revenue was
Financing supplied the operating deficit: FY2025 financing cash inflow was
Financial Health Signals
Can-Fite BioPharma Ltd. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Can-Fite BioPharma Ltd. scores -27.77, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4.7M) relative to total liabilities ($3.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Can-Fite BioPharma Ltd. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Can-Fite BioPharma Ltd. reported a net loss of $9.8M while operations used $8.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Can-Fite BioPharma Ltd. reported an operating loss of $9.9M against $284K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Can-Fite BioPharma Ltd. held $5.5M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
CANF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
CANF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q2'256-K | Q4'2420-F | Q2'2410-Q | Q4'2310-K | Q2'2310-Q | Q4'2210-K | Q2'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $9.5M+4.3% | $7.7M+30.4% | $9.1M-8.7% | $5.9M-46.3% | $10.0M+7.6% | $11.0M-25.2% | $9.3M-54.2% | $14.7M+52.3% |
| Current Assets | $9.4M+5.1% | $7.6M+30.8% | $9.0M-9.3% | $5.8M-46.6% | $9.9M+8.2% | $10.9M-25.2% | $9.2M-54.4% | $14.6M+52.7% |
| Cash & Equivalents | $5.5M+14.6% | $6.5M+36.8% | $4.8M+12.8% | $4.7M+36.5% | $4.3M+43.7% | $3.5M+102.0% | $3.0M-32.2% | $1.7M-77.3% |
| Short-Term Investments | $1K-80.0% | $2K-77.8% | $5K-73.7% | $9K-18.2% | $19K+137.5% | $11K-71.8% | $8K-96.6% | $39K-85.6% |
| Accounts Receivable | N/A | N/A | $0 | N/A | $0 | N/A | N/A | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3.9M+6.5% | $3.5M+2.7% | $3.7M-1.7% | $3.4M-17.2% | $3.7M-22.1% | $4.2M-14.3% | $4.8M-18.1% | $4.9M-15.2% |
| Current Liabilities | $2.7M+33.1% | $2.1M+6.7% | $2.1M+1.6% | $2.0M-11.0% | $2.0M-19.3% | $2.2M+3.7% | $2.5M-8.4% | $2.2M-8.7% |
| Non-Current Liabilities | $1.2M-27.0% | $1.4M-2.7% | $1.6M-5.4% | $1.5M-24.4% | $1.7M-25.2% | $1.9M-28.7% | $2.3M-26.5% | $2.7M-19.8% |
| Total Equity | $5.6M+2.9% | $4.2M+68.8% | $5.4M-12.9% | $2.5M-63.9% | $6.2M+39.6% | $6.9M-30.5% | $4.5M-68.9% | $9.9M+150.1% |
| Retained Earnings | -$176.2M-5.9% | -$171.2M-5.4% | -$166.4M-5.0% | -$162.4M-4.8% | -$158.5M-5.1% | -$155.1M-6.7% | -$150.8M-7.2% | -$145.3M-11.3% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
CANF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
CANF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Can-Fite BioPharma Ltd. CANF | FY2025 | $405K | -$9.8M | N/A | $4.7M | — |
| MetaVia Inc. MTVA | FY2025 | N/A | -$13.0M | N/A | $10.1M | — |
| NextCure, Inc. NXTC | FY2025 | N/A | -$55.8M | N/A | $22.7M | — |
| Cyclacel Pharmaceuticals, Inc CYCC | FY2025 | $747K | $3.0M | N/A | $15.2M | — |
| BioVie, Inc. BIVI | FY2026 | N/A | -$22.1M | N/A | $12.8M | — |
| Adaptimmune Therapeutics plc American ADAP | FY2024 | $178.0M | -$70.8M | -39.8% | $14.6M | 46/100 |
Where Can-Fite BioPharma Ltd. Ranks
Frequently Asked Questions
What is Can-Fite BioPharma Ltd.'s annual revenue?
Can-Fite BioPharma Ltd. (CANF) reported $405K in total revenue for fiscal year 2025. This represents a -39.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Can-Fite BioPharma Ltd.'s revenue growing?
Can-Fite BioPharma Ltd. (CANF) revenue declined by 39.9% year-over-year, from $674K to $405K in fiscal year 2025.
Is Can-Fite BioPharma Ltd. profitable?
No, Can-Fite BioPharma Ltd. (CANF) reported a net income of -$9.8M in fiscal year 2025.
What is Can-Fite BioPharma Ltd.'s EBITDA?
Can-Fite BioPharma Ltd. (CANF) had EBITDA of -$9.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Can-Fite BioPharma Ltd.'s return on equity (ROE)?
Can-Fite BioPharma Ltd. (CANF) has a return on equity of -175.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Can-Fite BioPharma Ltd.'s free cash flow?
Can-Fite BioPharma Ltd. (CANF) recorded an outflow of $9.0M in free cash flow during fiscal year 2025. This represents a -17.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Can-Fite BioPharma Ltd.'s operating cash flow?
Can-Fite BioPharma Ltd. (CANF) recorded an outflow of $8.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Can-Fite BioPharma Ltd.'s total assets?
Can-Fite BioPharma Ltd. (CANF) had $9.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Can-Fite BioPharma Ltd.'s capital expenditures?
Can-Fite BioPharma Ltd. (CANF) invested $2K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Can-Fite BioPharma Ltd. spend on research and development?
Can-Fite BioPharma Ltd. (CANF) invested $6.7M in research and development during fiscal year 2025.
What is Can-Fite BioPharma Ltd.'s current ratio?
Can-Fite BioPharma Ltd. (CANF) had a current ratio of 3.46 as of fiscal year 2025, which is generally considered healthy.
What is Can-Fite BioPharma Ltd.'s debt-to-equity ratio?
Can-Fite BioPharma Ltd. (CANF) had a debt-to-equity ratio of 0.70 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Can-Fite BioPharma Ltd.'s return on assets (ROA)?
Can-Fite BioPharma Ltd. (CANF) had a return on assets of -103.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Can-Fite BioPharma Ltd.'s P/E ratio?
Can-Fite BioPharma Ltd. (CANF) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $4.7M as of Oct 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Can-Fite BioPharma Ltd.'s price-to-sales ratio?
Can-Fite BioPharma Ltd. (CANF) trades at 11.5x sales, its market capitalization divided by revenue of $405K revenue, FY2025. The market capitalization is $4.7M as of Oct 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Can-Fite BioPharma Ltd.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Can-Fite BioPharma Ltd. (CANF) held $5.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.9M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Can-Fite BioPharma Ltd.'s Altman Z-Score?
Can-Fite BioPharma Ltd. (CANF) has an Altman Z-Score of -27.77, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Can-Fite BioPharma Ltd.'s Piotroski F-Score?
Can-Fite BioPharma Ltd. (CANF) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Can-Fite BioPharma Ltd.'s earnings high quality?
Can-Fite BioPharma Ltd. (CANF) reported a net loss of $9.8M while operations used $8.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Can-Fite BioPharma Ltd. cover its interest payments?
Can-Fite BioPharma Ltd. (CANF) reported an operating loss of $9.9M against $284K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.